• Patients living with non-radiographic axial spondyloarthritis, an often undiagnosed, chronic, painful and debilitating disease, now have an approved, clinically validated treatment

• FDA approval was based on the C-AXSPAND Phase 3 study in adults with non-radiographic axial spondyloarthritis, which demonstrated rapid and major improvement response with CIMZIA compared to placebo. Patients remained on common background medications, which could be adjusted at any point during the study

At UCB, we are inspired by patients and driven by science to deliver what patients value. We are committed to continuously working to advance science and embrace new knowledge — leading to the discovery of new solutions that help patients achieve their goals.

2018 marked the 90th anniversary of UCB. Since our creation in 1928, UCB has been characterized by a strong entrepreneurial spirit, determination and resilience, long term views, and a strong belief science and innovation would improve humanity.

Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)

Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

New Data Affirms Strength of UCB Immuno-Dermatology Portfolio